NCT05070286 is a clinical trial of Observational Study. in Multiple Sclerosis, sponsored by Oxford Brookes University.

Who is sponsoring NCT05070286?

NCT05070286 is sponsored by Oxford Brookes University.

What drugs are being tested in NCT05070286?

Interventions in NCT05070286: Observational Study..

What condition does NCT05070286 study?

NCT05070286 studies Multiple Sclerosis, Neuromyelitis Optica.

Is NCT05070286 still recruiting?

NCT05070286 is currently status unknown. Last updated 21 January 2022.

Last reviewed 2022-01-21 · How we verify

NCT05070286

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lifestyle Weight Management Program: Interviews and Stakeholder Meetings.

Status unknown Last updated 21 January 2022

What this trial tests

trial testing Observational Study. in Multiple Sclerosis in 45 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Oxford Brookes University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	45
Start date	1 January 2022
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across United Kingdom

Drugs / interventions tested

Observational Study.

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →
Neuromyelitis Optica — all drugs for Neuromyelitis Optica →

Sponsor

Oxford Brookes University

Who can join

Adults 10 to 25, any sex, with Multiple Sclerosis or Neuromyelitis Optica. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: An assessment by paediatric neurologists specializing in demyelinating conditions brought attention to the rapid weight change seen among patients recently diagnosed with, and receiving therapy for, neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS). An overview of the current literature pinpointed weight change as a concern, and identified fatigue and fear as limiting factors for participation in physical activity, with BMI trajectories in this population significantly higher compared to healthy peers. A look at current patient data highlighted extreme NMOSD cases where some patients' weight doubled in two years. There is currently no available research that addresses weight change and management in paediatric MS or NMOSD patients, but there is research to highlight the importance of maintaining health behaviours. The aim of this research is to co-develop a comprehensive lifestyle weight management program for this cohort. Methods: Unpinned by the Medical Research Council guidance for developing complex interventions, this research will involve a fourfold approach. It will build on a previously completed systematic review, and a secondary data analysis of current clinical data regarding weight changes in these populations. Semi-structured interviews will be conducted with patients, parents and clinicians in order to obtain qualitative data regarding the collective perspectives of nutrition, weight change and overall health. A list of factors will be identified and presented in a logic model. A program will then be designed, informed by previously gathered information and will be reviewed by a group of stakeholders via stakeholder meetings. This will output a program design, implementation and evaluation plan which will then be evaluated for feasibility. Recruitment, participation, implementation and adherence to the program will be tested. A patient, public involvement (PPI) approach will be taken, with a PPI panel of experts overseeing and guiding the project for its duration. Results: The results of this research will output a primary version of the lifestyle weight management program for paediatric patients with demyelinating conditions, ready for a feasibility trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other Oxford Brookes University trials

Trials by the same sponsor.

NCT06159296 — Effect of Inhaled Hydroxy Gas on Long COVID Symptoms · NA · unknown
NCT05888584 — Improving Access and Recruitment to Clinical Trials for Lung Cancer Patients · NA · recruiting
NCT05780164 — Improving Access to Lung Cancer Clinical Trials · recruiting
NCT05839860 — Salt Intake, Hydration Status and Gastrointestinal Discomfort During Fasting · NA · completed
NCT05412654 — Potassium Supplementation to Reduce Blood Pressure · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05070286 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oxford Brookes University
Last refreshed: 21 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05070286.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing